We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps

By LabMedica International staff writers
Posted on 28 May 2026

Colorectal cancer screening is a longstanding preventive priority, yet participation and follow-up remain uneven across patient groups. More...

Safety‑net primary care settings often face barriers that limit screening uptake among underserved populations. Addressing these gaps is essential to reduce disparities in outcomes. New findings demonstrate that mailing an at‑home stool test can substantially increase screening across diverse racial and ethnic groups.

At the University of North Carolina at Chapel Hill School of Medicine, investigators evaluated mailed fecal immunochemical tests (FIT) to increase colorectal cancer screening. The approach centered on sending FIT kits to patients due for screening at federally qualified health centers (FQHCs). For positive FIT results, the study team provided patient navigation to support follow‑up colonoscopy.

The analysis drew on data from two FQHC systems in North Carolina. A total of 3,734 patients were mailed FIT kits and participation in screening was assessed. Researchers reported an overall increase of 18.3 percentage points in colorectal cancer screening associated with the mailed‑test intervention.

Screening gains were similar among Hispanic, non‑Hispanic Black, and non‑Hispanic white patients. Among patients with a positive FIT who required follow‑up colonoscopy, the intervention’s effect was also similar across racial groups. However, Black patients were overall less likely to complete colonoscopy than white patients, indicating a need for additional, targeted strategies to support follow‑up among this population.

Results were published in the Annals of Family Medicine. The study team emphasized that mailed FIT programs can reach patients across demographic groups in community health settings while also highlighting persistent differences in colonoscopy completion that warrant focused interventions.

“This analysis showed that mailed colorectal cancer screening tests have the power to improve screening rates for diverse populations. This is really important, because we want these innovations in screening to improve outcomes among the hardest to reach populations and move the needle on colorectal cancer disparities,” said Anisha P. Ganguly, MD, MPH, a general internist at UNC Health and member of UNC Lineberger Comprehensive Cancer Center.

Related Links
UNC School of Medicine


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Unlike conventional molecular methods, VedaBio\'s CRISPR-based technology detects targets without requiring amplification (Photo courtesy of Veda Bio)

Target-Amplification-Free CRISPR Platform Demonstrates Molecular Detection in Under 10 Minutes

Molecular testing plays an important role in clinical diagnostics, but conventional workflows often require time-consuming procedures and specialized equipment, limiting their use outside centralized laboratories.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.